Recently, Hunan Tianjicaotang Pharmaceutical Co., Ltd., a subsidiary of Tat Ka Wai Hong Pharmaceutical Group, received the “Drug Registration Certificate” from the National Medical Products Administration for its Oseltamivir Phosphate Granules. The product has successfully passed the consistency evaluation, with the approval number: Guoyao Zhunzi H20249791.

Oseltamivir, a specific inhibitor of neuraminidase, effectively prevents the release of mature influenza viruses from host cells, thus halting the spread of the virus within the human body. It is widely used to treat both influenza A and B. Oseltamivir is classified under Category B of national medical insurance drugs.

Tat Ka Wai Hong continues to invest heavily in pharmaceutical technology and product R&D. The company has established a nearly 10,000 square meter R&D center, recruiting scientific talents from both domestic and international markets to form a high-quality team. Through independent R&D and collaborations with universities and research institutions, the company is advancing the research, development, and production of original chemical drugs, new traditional Chinese medicines, and health products. By leading in innovation, Tat Ka Wai Hong aims to strengthen its core competitiveness. In the future, the company plans to launch additional products, including Ezetimibe and Atorvastatin Calcium Tablets, as well as Sacubitril and Valsartan Sodium Tablets.